Abstract
Expert Rev. Cardiovasc. Ther. 8(9), 1207–1210 (2010) “Two trials with the everolimus-eluting stent demonstrated a significant reduction in angiographic in-stent and in-segment late lumen loss compared with the first-generation TAXUS Express paclitaxel-eluting stent, and noninferiority in major clinical end points…”
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
